Steven Richieri

Steven has nearly 40 years of experience in the health care industry and has a broad background in biotechnology, pharmaceutical and medical device product development and research.  He also has extensive experience in the US Food and Drug Administration’s regulatory process and has been responsible for taking a number of products from the research laboratory to the clinic for stroke, HIV, autoimmune diseases, cancer, allergic rhinitis, and traumatic brain injury (TBI); the latter of which culminated in the first world-wide approval of a diagnostic blood test for mild TBI in the US in 2018.  Steven has held senior executive positions at Banyan Biomarkers, Inc., PhotoThera, Inc., Egea Biosciences, Inc. (a wholly owned subsidiary of Centocor Inc.), The Immune Response Corporation and Dura Pharmaceuticals. He is also the co-founder and former CEO of American Life Science Pharmaceuticals, a start-up drug discovery company focused on finding novel therapeutics to treat neurodegenerative and age-related disorders and NuVista Technology Corporation, a privately held medical device company. He has been on the Tempo Board of Directors since 2016 and is an early investor in Tempo Therapeutics.